RESUMEN
No disponible
No disponible
Asunto(s)
Humanos , Relaciones Médico-Paciente , Atención al Paciente/tendencias , Discusiones Bioéticas , Reproducción/ética , Innovación OrganizacionalRESUMEN
No disponible
No disponbile
Asunto(s)
Técnicas de Diagnóstico Obstétrico y Ginecológico/ética , Técnicas Reproductivas Asistidas/economía , Diagnóstico Preimplantación/ética , Diagnóstico Prenatal/ética , Recien Nacido Prematuro , Tecnología Biomédica/legislación & jurisprudencia , Síndrome de Hiperestimulación Ovárica/complicaciones , Embarazo Múltiple , Diagnóstico Preimplantación , Cuidados para Prolongación de la Vida/ética , Atención al Paciente , Consentimiento Informado , Edad Materna , Bioética , Derechos del Paciente , Ética Profesional , Competencia Profesional , Eutanasia , Terapias Fetales , Neoplasias de los Genitales FemeninosRESUMEN
PURPOSE: The sex steroid control of the endometrial cycle is mediated by transcription factors, four of which are the estrogen and progesterone receptors, c-jun and c-fos, all expressed by the endometrium. The aim of this study was to analyze the distribution of the transcription factors in the different endometrial compartments during natural cycles. METHODS: We studied 53 reproductively-normal women, of whom 26 were in the proliferative phase and 27 in the secretory phase. An endometrial biopsy was performed and serum values of LH, FSH, estradiol, and progesterone were determined. We studied the expression of transcription factors using monoclonal antibodies. RESULTS: A correlation between estrogen receptor and c-jun and c-fos expression was observed in stroma and epithelia, and progesterone receptor expression correlated with c-jun expression in epithelia. C-jun and c-fos presented greater expression in the proliferative phase than in the secretory phase, in the stroma and in both epithelia. No relation was found between estradiol serum levels and any transcription factor, but progesterone serum levels correlated significantly with most such factors. CONCLUSION: The two proto-oncogenes could play a decisive role in regulating the endometrial cycle; they could mediate the effects induced by sex steroid, and could be related to other transcription factors.
Asunto(s)
Endometrio/metabolismo , Ciclo Menstrual , Proteínas Proto-Oncogénicas c-fos/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Receptores de Estrógenos/metabolismo , Receptores de Progesterona/metabolismo , Endometrio/patología , Células Epiteliales/metabolismo , Células Epiteliales/patología , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Progesterona/sangre , Células del Estroma/metabolismo , Células del Estroma/patologíaRESUMEN
Dexketoprofen, the pure S(+)-enantiomer of ketoprofen, is a promising new analgesic, but few clinical trials have yet examined its efficacy and tolerability. In this study, patients with a history of primary dysmenorrhea were treated with dexketoprofen doses of 12.5 and 25 mg, ketoprofen 50 mg, and placebo using a randomized, four-way crossover design. Efficacy analyses showed that dexketoprofen 12.5 and 25 mg and racemic ketoprofen 50 mg significantly reduced pain intensity compared with placebo from 1 h after dose to 4-6 h after dose. Interestingly, dexketoprofen at 12.5 mg was significantly superior to placebo at 30 min after dose. Mean pain relief scores also demonstrated that both doses of dexketoprofen and racemic ketoprofen were significantly superior to placebo at 1-6 h after the first dose. No indices of analgesic efficacy showed any significant differences between the two doses of dexketoprofen or between dexketoprofen and ketoprofen. After repeated dose administration, similar results were obtained. There were no significant effects of any treatment on activities of daily living, menstrual flow, or associated symptoms. Dexketoprofen was effective, well tolerated, and had no difference in the incidence of adverse events compared to ketoprofen or placebo.
